I am a phage therapy researcher and co-founder at ClotGuard, while in my grade 10 year. My latest research involves working with CRISPR-Cas3 systems alongside phage therapy to engineer innovative therapies to combat antibiotic resistance and be implemented in other fields. My main work is in developing the ClotGuard patch, a nanobot-powered wound-care technology designed to detect and mitigate bleeding autonomously. I’m in my second year program at TKS called Activate, where I continue to develop my projects and work with companies on the real-world challenges they face.

Contact Isavella for more info.